| According to a new report by IMARC titled “Indian Vaccine Market Report and Forecast 2020-2025”, the Indian�vaccine market�reached a value of INR 94 Billion in 2019.
Vaccines refer to biological preparations consisting of an agent that is similar to a disease-causing pathogen to offer immunization against specific diseases. They are administered orally, by aerosol or through injections as a preventive measure for a number of diseases such as polio, measles, influenza and rabies. India currently represents one of the leading manufacturers and suppliers of vaccines in the world. It solely accounts for around 60% of the total vaccines supplied to the UNICEF, since the cost of manufacturing and clinical trials in India is relatively lower than in developed countries. Moreover, technological advancements and improved cold chain storage facilities have led to increased vaccine production capacity in the country.
Request for a free sample copy of this report: https://www.imarcgroup.com/indian-vaccine-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Market Trends:
One of the major drivers of the Indian vaccine market is the strong government support to the manufacturers. Steady government funding and successful initiatives have resulted in considerable market development over the years. Also, various government-funded campaigns have created widespread health awareness among the masses. For instance, the Universal Immunization Program (UIP) introduced by the Government with the aim to increase immunization coverage against vaccine-preventable diseases in the country has significantly boosted the demand for vaccines.
Besides this, the growing investments from private sector players to develop and distribute vaccines throughout the country, as well as in the international market, has strengthened the present vaccine manufacturing infrastructure. Apart from this, continuous research and development (R&D) activities have enabled manufacturers to introduce new and improved vaccines in the market. Some of the other factors positively influencing the market growth are increasing population, elevating incomes, improving cold chain logistics and active NGO participation. Looking forward, the market value is projected to reach INR 252 Billion by 2025, expanding at a CAGR of 17.8% during the forecast period (2020-2025).
Market Summary:
The market has been analyzed on the basis of various monovalent and combined vaccines into Bacillus Calmette-Guerin (BCG), Haemophilus influenzae type b (Hib), Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus and Pertussis (DPT), Oral Polio Vaccine (OPV), Measles, Mumps and Rubella (MMR), Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, Human Papillomavirus (HPV), Hexavalent and Dengue.
The competitive landscape of the market has also been examined, with some of the key players being: GlaxoSmithKline PLC (GSK), Sanofi (SNY), Serum Institute of India, Panacea Biotec Limited., Pfizer, Inc. (PFE)., Novartis AG (NVS), VHB Life Sciences Limited, Cadila Healthcare Ltd. (Zydus Cadila) and Merck & Co., Inc. NYSE: MRK & Dohme Corporation (MSD).
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/indian-vaccine-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email:�[email protected]
Tel No D) 91 120 433 0800
Americas:- 1 631 791 1145 | Africa and Europe :- 44-702-409-7331 | Asia: 91-120-433-0800, 91-120-433-0800 |
| Recently Spotted MembersNo members found. Be the first. |
D) 91 120 433 0800
